Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Avacta Group Plc (LSE:AVCT): FTSE AIM 100 / FTSE AIM All-Share Small-Cap Growth Stock in Focus as Investors Track the Next Catalyst

• The stock is classified as a small-cap growth stock; this is a descriptive market classification, not anInvestmentrating.

Ankur Sharma | 13 November 2026

CRISPR Therapeutics Corporation (LSE:CRTX): NASDAQ Global Select / London depositary listing Mid-Cap Growth Stock in Focus as Investors Track the Next Catalyst

• The stock is classified as a mid-cap growth stock; this is a descriptive market classification, not anInvestmentrating.

Ankur Sharma | 13 November 2026

EDX Medical Group PLC (LSE:EDX): FTSE AIM All-Share Small-Cap Growth Stock in Focus as Investors Track the Next Catalyst

• The stock is classified as a small-cap growth stock; this is a descriptive market classification, not anInvestmentrating.

Ankur Sharma | 13 November 2026

Faron Pharmaceuticals Oy (LSE:FARN): FTSE AIM All-Share Small-Cap Growth Stock in Focus as Investors Track the Next Catalyst

• The stock is classified as a small-cap growth stock; this is a descriptive market classification, not anInvestmentrating.

Ankur Sharma | 13 November 2026

hVIVO plc (LSE:HVO): FTSE AIM All-Share Small-Cap Growth Stock in Focus as Investors Track the Next Catalyst

• The stock is classified as a small-cap growth stock; this is a descriptive market classification, not anInvestmentrating.

Ankur Sharma | 13 November 2026

Image Scan Holdings plc (LSE:IGE): FTSE AIM All-Share Small-Cap Growth Stock in Focus as Investors Track the Next Catalyst

• The stock is classified as a small-cap growth stock; this is a descriptive market classification, not anInvestmentrating.

Ankur Sharma | 13 November 2026

RUA Life Sciences plc (LSE:RUA): FTSE AIM All-Share Small-Cap Growth Stock in Focus as Investors Track the Next Catalyst

• The stock is classified as a small-cap growth stock; this is a descriptive market classification, not anInvestmentrating.

Ankur Sharma | 13 November 2026

Shield Therapeutics plc (LSE:STX): FTSE AIM All-Share Small-Cap Growth Stock in Focus as Investors Track the Next Catalyst

• The stock is classified as a small-cap growth stock; this is a descriptive market classification, not anInvestmentrating.

Ankur Sharma | 13 November 2026

Can Genus's China Joint Venture and £60m Buyback Keep Its Animal Genetics Engine Humming? (LSE:GNS)

Genus plc (LSE:GNS) shares eased 1.13% to 2,268.0p on 13 November 2026. The animal genetics group was in focus following its preliminary results for the year ended 30 June 2026, published on 10 September 2026.

Divya Sood | 13 November 2026

Can Oxford Biomedica's Record Client Wins and £500m Ambition Fuel Its Gene Therapy Growth? (LSE:OXB)

Oxford Biomedica plc (LSE:OXB) shares eased 1.50% to 527.0p on 13 November 2026. The cell and gene therapy manufacturer was in focus following its half-year results for the six months ended 30 June 2026, published on 22 September 2026.

Divya Sood | 13 November 2026
Support

Hi! How can we help you today?

Loading…